1
|
Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapy. Signal Transduct Target Ther 2018; 3:12. [PMID: 29713497 PMCID: PMC5923205 DOI: 10.1038/s41392-018-0016-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2018] [Revised: 03/03/2018] [Accepted: 03/06/2018] [Indexed: 01/01/2023] Open
Abstract
Cancer of unknown primary (CUP) is a recalcitrant disease with poor prognosis because it lacks standard first-line therapy. CUP consists of diverse malignancy groups, making personalized precision therapy essential. The present study aimed to identify an effective therapy for a CUP patient using a patient-derived orthotopic xenograft (PDOX) model. This paper reports the usefulness of the PDOX model to precisely identify effective and ineffective chemotherapy and to compare the efficacy of S. typhimurium A1-R with first-line chemotherapy using the CUP PDOX model. The present study is the first to use a CUP PDOX model, which was able to precisely distinguish the chemotherapeutic course. We found that a carboplatinum (CAR)-based regimen was effective for this CUP patient. We also demonstrated that S. typhimurium A1-R was more effective against the CUP tumor than first-line chemotherapy. Our results indicate that S. typhimurium A1-R has clinical potential for CUP, a resistant disease that requires effective therapy. The genetically-engineered strain of Salmonella A1-R effectively targets human metastatic cancers of unknown primary (CUP) in a mouse model. In up to 5% of advanced cancer diagnosis the primary site of cancer growth cannot be identified. In these cases, prognosis is poor as the most appropriate therapies are determined by the cancer’s tissue of origin. A study led by US researchers Shree Ram Singh, Fritz C. Eilber and Robert M. Hoffman examined the effect of four standard chemotherapeutic drugs and Salmonella A1-R on CUP progression in mice implanted with a lymph node tumor resected from a patient’s neck. To mimic the tumor microenvironment in the patient, the tumor was placed in the corresponding anatomical site in mice. This model showed that only carboplatinum and Salmonella A1-R were able to suppress CUP tumor growth.
Collapse
|
2
|
Lhuillier C, Barjon C, Niki T, Gelin A, Praz F, Morales O, Souquere S, Hirashima M, Wei M, Dellis O, Busson P. Impact of Exogenous Galectin-9 on Human T Cells: CONTRIBUTION OF THE T CELL RECEPTOR COMPLEX TO ANTIGEN-INDEPENDENT ACTIVATION BUT NOT TO APOPTOSIS INDUCTION. J Biol Chem 2015; 290:16797-811. [PMID: 25947381 DOI: 10.1074/jbc.m115.661272] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2015] [Indexed: 11/06/2022] Open
Abstract
Galectin-9 (gal-9) is a multifunctional β-galactoside-binding lectin, frequently released in the extracellular medium, where it acts as a pleiotropic immune modulator. Despite its overall immunosuppressive effects, a recent study has reported bimodal action of gal-9 on human resting blood T cells with apoptosis occurring in the majority of them, followed by a wave of activation and expansion of Th1 cells in the surviving population. Our knowledge of the signaling events triggered by exogenous gal-9 in T cells remains limited. One of these events is cytosolic calcium (Ca(2+)) release reported in some murine and human T cells. The aim of this study was to investigate the contribution of Ca(2+) mobilization to apoptotic and nonapoptotic effects of exogenous gal-9 in human T cells. We found that the T cell receptor (TCR)-CD3 complex and the Lck kinase were required for Ca(2+) mobilization but not for apoptosis induction in Jurkat cells. These data were confirmed in human CD4(+) T cells from peripheral blood as follows: a specific Lck chemical inhibitor abrogated Ca(2+) mobilization but not apoptosis induction. Moreover, Lck activity was also required for the production of Th1-type cytokines, i.e. interleukin-2 and interferon-γ, which resulted from gal-9 stimulation in peripheral CD4(+) T cells. These findings indicate that gal-9 acts on T cells by two distinct pathways as follows: one mimicking antigen-specific activation of the TCR with a mandatory contribution of proximal elements of the TCR complex, especially Lck, and another resulting in apoptosis that is independent of this complex.
Collapse
Affiliation(s)
- Claire Lhuillier
- From the Université Paris-Sud, 15 Rue Georges Clémenceau, 91400, Orsay, France, the CNRS, UMR 8126, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France, the Cellvax, Ecole Nationale Vétérinaire d'Alfort, 7 Avenue du Général de Gaulle, 94704 Maisons-Alfort Cedex, France
| | - Clément Barjon
- From the Université Paris-Sud, 15 Rue Georges Clémenceau, 91400, Orsay, France, the CNRS, UMR 8126, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France, the Cellvax, Ecole Nationale Vétérinaire d'Alfort, 7 Avenue du Général de Gaulle, 94704 Maisons-Alfort Cedex, France
| | - Toshiro Niki
- the Department of Immunology and Immunopathology, Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan, the GalPharma Co., Ltd., Takamatsu, Kagawa 761-0301, Japan
| | - Aurore Gelin
- the CNRS, UMR 8126, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France
| | - Françoise Praz
- INSERM, UMR-S 938, Centre de Recherche Saint-Antoine, 75012, Paris, France, the Sorbonne Universités, UPMC Université Paris 06, UMR-S 938, Centre de Recherche Saint-Antoine, 75012, Paris, France
| | - Olivier Morales
- CNRS, UMR 8161 Groupe IRCV, Institut de Biologie de Lille, 1 Rue du Pr. Calmette, 59021 Lille, France
| | - Sylvie Souquere
- From the Université Paris-Sud, 15 Rue Georges Clémenceau, 91400, Orsay, France, UMR 8122, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France, and
| | - Mitsuomi Hirashima
- the Department of Immunology and Immunopathology, Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan, the GalPharma Co., Ltd., Takamatsu, Kagawa 761-0301, Japan
| | - Ming Wei
- the Cellvax, Ecole Nationale Vétérinaire d'Alfort, 7 Avenue du Général de Gaulle, 94704 Maisons-Alfort Cedex, France
| | - Olivier Dellis
- From the Université Paris-Sud, 15 Rue Georges Clémenceau, 91400, Orsay, France, INSERM, UMR-S 757, Bâtiment 440/443, Rue des Adèles, 91405 Orsay, France
| | - Pierre Busson
- From the Université Paris-Sud, 15 Rue Georges Clémenceau, 91400, Orsay, France, the CNRS, UMR 8126, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France,
| |
Collapse
|
3
|
Chauchereau A, Al Nakouzi N, Gaudin C, Le Moulec S, Compagno D, Auger N, Bénard J, Opolon P, Rozet F, Validire P, Fromont G, Fizazi K. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. Exp Cell Res 2010; 317:262-75. [PMID: 20974126 DOI: 10.1016/j.yexcr.2010.10.012] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2010] [Revised: 09/20/2010] [Accepted: 10/16/2010] [Indexed: 01/06/2023]
Abstract
Deciphering molecular pathways involved in the early steps of prostate oncogenesis requires both in vitro and in vivo models derived from human primary tumors. However the few recognized models of human prostate epithelial cancer originate from metastases. To date, very few models are proposed from primary tumors and immortalizing normal human prostate cells does not recapitulate the natural history of the disease. By culturing human prostate primary tumor cells onto human epithelial extra-cellular matrix, we successfully selected a new prostate cancer cell line, IGR-CaP1, and clonally-derived subclones. IGR-CaP1 cells, that harbor a tetraploid karyotype, high telomerase activity and mutated TP53, rapidly induced subcutaneous xenografts in nude mice. Furthermore, IGR-CaP1 cell lines, all exhibiting negativity for the androgen receptor and PSA, express the specific prostate markers alpha-methylacyl-CoA racemase and a low level of the prostate-specific membrane antigen PSMA, along with the prostate basal epithelial markers CK5 and CK14. More importantly, these clones express high CD44, CD133, and CXCR4 levels associated with high expression of α2β1-integrin and Oct4 which are reported to be prostate cancer stemness markers. RT-PCR data also revealed high activation of the Sonic Hedgehog signalling pathway in these cells. Additionally, the IGR-CaP1 cells possess a 3D sphere-forming ability and a renewal capacity by maintaining their CSC potential after xenografting in mice. As a result, the hormone-independent IGR-CaP1 cellular clones exhibit the original features of both basal prostate tissue and cancer stemness. Tumorigenic IGR-CaP1 clones constitute invaluable human models for studying prostate cancer progression and drug assessment in vitro as well as in animals specifically for developing new therapeutic approaches targeting prostate cancer stem cells.
Collapse
Affiliation(s)
- Anne Chauchereau
- Prostate Cancer Group, INSERM U981, Institut Gustave Roussy, Villejuif F-94805, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|